ATXI — Avenue Therapeutics, Inc. Dilution Risk Tracker

Avenue Therapeutics, Inc. (ATXI) has a DilutionScore of 47/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

DilutionWatch tracks 545,454 outstanding warrants for ATXI. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window. Cash runway is a key watch item: ATXI has approximately 14 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for ATXI in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for ATXI alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.